Clazosentan (Actelion).
Clazosentan, an endothelin ETA antagonist, is under development by Actelion (formerly Axovan), under license from F Hoffman-La Roche, for the potential prevention of cerebral infarction and ischemia induced by cerebral vasospasm following subarachnoid hemorrhage. Results from the phase IIb portion of a phase IIb/III clinical study are expected in the first half of 2006.
University of Leipzig, Germany. uhld@medizin.uni-leipzig.de
Dirk
D
Uhlmann
D017326:Clinical Trials, Phase III as Topic; D004146:Dioxanes / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D019332:Endothelin-1 / Q000037:antagonists & inhibitors*; D006801:Humans; D008968:Molecular Conformation; D011725:Pyridines / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy*; D013449:Sulfonamides / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D013777:Tetrazoles / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D014661:Vasoconstriction / Q000187:drug effects*; D014662:Vasoconstrictor Agents / Q000737:chemistry / Q000627:therapeutic use*; D020301:Vasospasm, Intracranial / Q000188:drug therapy*
D004146:Dioxanes; D019332:Endothelin-1; D011725:Pyridines; D011743:Pyrimidines; D013449:Sulfonamides; D013777:Tetrazoles; D014662:Vasoconstrictor Agents; C109641:clazosentan